BSS
  16 Nov 2021, 11:10

Pfizer, BioNTech, Moderna making $1,000 profit every second: analysis

  WASHINGTON, Nov 16, 2021 (BSS/AFP) - Pfizer, BioNTech and Moderna are
making combined profits of $65,000 every minute from their highly successful
Covid-19 vaccines while the world's poorest countries remain largely
unvaccinated, according to a new analysis.

  The companies have sold the vast majority of their doses to rich countries,
leaving low-income nations in the lurch, said the People's Vaccine Alliance
(PVA), a coalition campaigning for wider access to Covid vaccines, which
based its calculations on the firms' own earning reports.

  The Alliance estimates that the trio will make pre-tax profits of $34
billion this year between them, which works out to over $1,000 a second,
$65,000 a minute or $93.5 million a day.

  "It is obscene that just a few companies are making millions of dollars in
profit every single hour, while just two percent of people in low-income
countries have been fully vaccinated against coronavirus," Maaza Seyoum of
the African Alliance and People's Vaccine Alliance Africa said.

  "Pfizer, BioNTech and Moderna have used their monopolies to prioritise the
most profitable contracts with the richest governments, leaving low-income
countries out in the cold."

  Pfizer and BioNTech have delivered less than one percent of their total
supplies to low-income countries while Moderna has delivered just 0.2
percent, the PVA said.

  Currently, 98 percent of people in low-income countries have not been fully
vaccinated.

  The three companies' actions are in contrast to AstraZeneca and Johnson &
Johnson, which provided their vaccines on a not-for-profit basis, though both
have announced they foresee ending this arrangement in future as the pandemic
winds down.

  PVA said that despite receiving public funding of more than $8 billion,
Pfizer, BioNTech and Moderna have refused calls to transfer vaccine
technology to producers in low- and middle-income countries via the World
Health Organization, "a move that could increase global supply, drive down
prices and save millions of lives."

  "In Moderna's case, this is despite explicit pressure from the White House
and requests from the WHO that the company collaborate in and help accelerate
its plan to replicate the Moderna vaccine for wider production at its mRNA
hub in South Africa," the group said.

  While Pfizer CEO Albert Bourla has dismissed technology transfer as
"dangerous nonsense," the WHO's decision to grant emergency use approval to
the Indian-developed Covaxin earlier this month proves that developing
countries have the capacity and expertise, PVA added.

  PVA, whose 80 members include the African Alliance, Global Justice Now,
Oxfam, and UNAIDS, is calling for pharmaceutical corporations to immediately
suspend intellectual property rights for COVID vaccines by agreeing to a
proposed waiver of World Trade Organisation's TRIPS agreement.

  More than 100 nations, including the United States, back that move, but it
is being blocked by rich countries including the UK and Germany.